Navigation Links
Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
Date:10/28/2008

HELSINKI, October 28 /PRNewswire/ -- Northern Antibiotics Ltd., the developer of novel polymyxin derivatives for the treatment of infections caused by multidrug-resistant Gram-negative bacteria, revealed today animal efficacy and pharmacokinetic data from their NAB compounds at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC.

Northern Antibiotics has developed two series of novel polymyxin (NAB) compounds (Vaara M. et al., 2008, Antimicrob. Agents Chemother. 52:3229). The compounds of the first series (lead compound, NAB739) are directly antibacterial against polymyxin-susceptible Gram-negative enteric bacteria such as Escherichia coli, Klebsiella spp, and Enterobacter spp., as well as against Acinetobacter baumannii. The representatives of the second series (lead compound, NAB7061) have only a weak direct action but sensitize in a very remarkable degree these Gram negative bacteria to antibiotics such as macrolides, rifampin, and others. The compounds of both series carry only three positive charges whereas the notoriously nephrotoxic old polymyxins (colistin, polymyxin B) carry a total of five positive charges.

The in vivo efficacy of NAB739 and NAB7061 was evaluated in a murine peritoneal infection model using the virulent, encapsulated E. coli strain IH3080 (K1:O18) as the challenge organism. As low a dose as 1 mg/kg (body weight) of NAB739, given at 1h postinfection and repeated at 3 h postinfection, displayed potent bactericidal effect. The bacterial counts in the treated animals were 4.8 log10 lower in the mice treated with NAB739 than in the untreated control mice.

Furthermore, while NAB7061 (5 mg/kg) alone as well as erythromycin (20 mg/kg) alone were ineffective in the murine peritoneal model, the bacterial counts in mice that received their combination were 2.9 log10 lower than in the untreated controls (dosing time schedule as above with NAB739). Accordingly, the in vivo efficacy studies corroborate the previo
'/>"/>

SOURCE Northern Antibiotics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
2. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
3. Solving the Z rings mysteries may lead to new antibiotics
4. Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail
5. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
6. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
7. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
8. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Deerfield Management ... Healthcare Innovations Fund, L.P., which will invest in groundbreaking ... in genetic diseases, cancer, and orphan diseases. The venture ... transform how therapeutics are developed and improve the way ... one of the largest healthcare-focused venture funds in the ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... SINGAPORE , July 28, 2015  Faced ... treatments that are palliative rather than symptomatic, the ... With few existing therapies capable of curing or ... providers are starting to look towards regenerative medicine ... represents a new paradigm in human health with ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... of the equation , ,Identity theft has seen the ... three years. The United States is faced with an ever-changing ... both sides of the equation, organizational and consumer. , ... to a new report from the Federal Trade Commission (FTC). ...
... pioneer company looks to reclaim lost ground , ,CHIPPEWA FALLS, ... operating out of offices on Lowater Road here in its hometown, ... wonderful heights. , ,With its next-generation X1, on the market since ... toward the future with a twinkle in its corporate eye that, ...
... often been regarded as the economic motor of the European ... of Scandinavia, to the east of the U.K. and France, ... the east European countries of Poland, the Czech Republic and ... not only one of Europes largest populations but considering ...
Cached Biology Technology:Are You Ready for Identity Theft? 2Are You Ready for Identity Theft? 3Are You Ready for Identity Theft? 4Are You Ready for Identity Theft? 5Are You Ready for Identity Theft? 6Are You Ready for Identity Theft? 7Cray Rides Again 2Cray Rides Again 3German Life Science Oktoberfest Comes to the Midwest 2German Life Science Oktoberfest Comes to the Midwest 3German Life Science Oktoberfest Comes to the Midwest 4German Life Science Oktoberfest Comes to the Midwest 5German Life Science Oktoberfest Comes to the Midwest 6
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... ARBOR, Mich.A new power scheme for cardiac pacemakers turns ... Engineering researchers at the University of Michigan designed ... heartbeats through the chest and converts it to electricity ... mini-medical machines send electrical signals to the heart to ...
... of the shark and are often removed from the body, which ... many countries allow the fins to be landed detached from shark ... cent of the total shark catch. New University of British Columbia ... A study published this week in the journal Fish ...
... are a rarely collected group of insects. Adults are considered ... of juvenile spiders. Eight genera are recorded in Australasia, including ... of large, hairy, often metallic coloured adults whose larvae specialize ... and funnel web spiders. In this study, four ...
Cached Biology News:Heart-powered pacemaker could one day eliminate battery-replacement surgery 2Law that regulates shark fishery is too liberal: UBC study 2
... observations of cell cultures under precise, controlled ... strain parameters in addition to a microscope ... chamber used by the ST-195 is compatible ... can be used with Nikon, Olympus, Leica, ...
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... Kit is designed for concentration and ... samples. Proteomics sample analysis is often ... impurities such as buffers, salts and ... interfere with electrophoretic separations or enzymatic ...
... carrier proteins to simplify the production ... Carrier Proteins are commonly used carriers ... heterobifunctional cross-linker (Sulfo-SMCC). This activation results ... Thus allowing the maleimide-activated carrier ...
Biology Products: